Marked increase in steady-state serum levels achieved with itraconazole oral solution compared with capsule formulation [4]

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 908-909

  Freeman, Josh ^a,c   Heshmati, Amy ^a   Holland, David ^a   Ticehurst, Rob ^b   Lang, Selwyn ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Absorption; Bioavailability; Therapeutic drug monitoring

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; C REACTIVE PROTEIN; HYDROXYITRACONAZOLE; ITRACONAZOLE;

ADULT; BEVERAGE; CASE REPORT; COCCIDIOIDOMYCOSIS; DISEASE COURSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; HUMAN; INDUSTRIAL WORKER; LETTER; LUMBOSACRAL SPINE; MALE; STEADY STATE;

ADULT; CAPSULES; HUMANS; ITRACONAZOLE; MALE; SERUM; SOLUTIONS;

EID: 34548752796     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm272     Document Type: Letter

References (7)

1. Odds FC, Vanden Bossche H. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vltro. J. Antimicrob Chemother 2000; 45: 371-3.
2. Information for Healthcare Professionals. Sporanox Capsules Datasheet New Zealand: Medsafe, 8 March 2006. www.medsafe.govt.nz/profs/datasheet/s/sporanoxcap.htm (9 July 2007, date last accessed).
3. Poirier J-M, Berlioz F, Isnard F et al. Marked intra- and interpatient variability of itraconazole steady state plasma concentrations. Thérapie 1996; 51: 163-7.
4. Information for Healthcare Professionals.Sporanox Oral Solution. New Zealand: Medsafe, W March 2006 http://www.medsafe.govt.nz/profs/ datasheet/s/sporanoxsol.htm (9 July 2007, date last accessed).
5. Poirier J-M, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998; 35: 461-73.
6. Buchkowsky SS, Partovi N, Ensom MHH. Clinical pharmacokinetic monitoring of itraconazole Is warranted in only a subset of patients. Ther Drug Monit 2005; 27; 322-33
7. Redmann S, Charles BG. Markedly increased itraconazole (ICZ) plasma levels in cystic fibrosis (CF) patients after switching from capsules to oral solution - two case studies. Clin Exp Pharmacol Physiol 200.4; 31 Suppl 1: Al07.